文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancers.

作者信息

Liang Hengchang, Tang Chunling, Sun Yue, Wang Mingwei, Tong Tong, Gao Qinquan, Xie Hui, Tan Tao

机构信息

Faulty of Applied Sciences, Macao Polytechnic University, Macao, 999078, People's Republic of China.

Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 9RT, UK.

出版信息

Discov Oncol. 2024 Dec 18;15(1):798. doi: 10.1007/s12672-024-01684-9.


DOI:10.1007/s12672-024-01684-9
PMID:39692937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11655734/
Abstract

PURPOSE: The aim of this study was to investigate the causal relationship between low-density lipoprotein cholesterol (LDL-C) and five cancers (breast, cervical, thyroid, prostate and colorectal) using the Mendelian Randomization (MR) method, with a view to revealing the potential role of LDL-C in the development of these cancers. METHODS: We used gene variant data and disease data from the Genome-Wide Association Study (GWAS) database to assess the causal relationship between LDL-C and each cancer by Mendelian randomisation analysis methods such as inverse variance weighting and MR-Egger. Specifically, we selected Proprotein convertase subtilisin/kexin type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), genes associated with LDL-C levels, as instrumental variables, extracted the corresponding single nucleotide polymorphism (SNP) data and analysed the associations of these SNPs with five cancers.In addition, sensitivity analyses and heterogeneity tests were performed to ensure the reliability of the results. RESULTS: The analyses showed that when using HMGCR gene, LDL-C were significantly and positively associated with breast (OR:1.200, 95% CI:1.082-1.329, p = 0.001), prostate (OR:1.198, 95% CI:1.050-1.366, p = 0.007), and thyroid cancers (OR:8.291, 95% CI:3.189- 21.555, p = 0.00001) were significantly positively correlated, whereas they were significantly negatively correlated with colorectal cancer (OR:0.641, 95% CI:0.442-0.928, p = 0.019); the results for cervical cancer were not significant (p = 0.050). When using the PCSK9 gene, LDL-C levels were significantly and positively associated with breast (OR:1.107, 95%:CI 1.031-1.187, p = 0.005) and prostate (OR:1.219, 95%:CI 1.101-1.349, p = 0.0001) cancers, but not with cervical (p = 0.294), thyroid cancer (p = 0.759) and colorectal cancer ( p = 0.572). CONCLUSION: Analyses using both the HMGCR and PCSK9 genes have shown that LDL-C may be a potential risk factor for breast and prostate cancer, while analyses of the HMGCR gene have also suggested that LDL-C may increase the risk of thyroid cancer and decrease the risk of colorectal cancer.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/bccbff7d3fb7/12672_2024_1684_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/fabdf79e2e63/12672_2024_1684_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/5b0d558a5b83/12672_2024_1684_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/bccbff7d3fb7/12672_2024_1684_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/fabdf79e2e63/12672_2024_1684_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/5b0d558a5b83/12672_2024_1684_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7631/11655734/bccbff7d3fb7/12672_2024_1684_Fig3_HTML.jpg

相似文献

[1]
Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancers.

Discov Oncol. 2024-12-18

[2]
Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.

Breast Cancer Res. 2022-2-12

[3]
Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.

Eur J Prev Cardiol. 2024-7-23

[4]
Causal Association Between Cholesterol-Lowering Drugs and Diabetic Microvascular Complications: A Drug-Target Mendelian Randomization Study.

J Diabetes Res. 2025-2-28

[5]
Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.

Front Endocrinol (Lausanne). 2024

[6]
Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation.

Lipids Health Dis. 2024-10-2

[7]
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

PLoS Med. 2023-1

[8]
Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.

J Nutr. 2022-5-5

[9]
Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.

Front Endocrinol (Lausanne). 2023

[10]
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting.

Genes (Basel). 2024-1-21

引用本文的文献

[1]
Integrative approach to decipher pharmacological mechanism of Cinnamomum zeylanicum essential oil in prostate cancer.

Med Oncol. 2025-3-12

本文引用的文献

[1]
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Antioxidants (Basel). 2024-7-14

[2]
Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients.

Nutrients. 2024-2-14

[3]
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting.

Genes (Basel). 2024-1-21

[4]
Role of Prehabilitation and Rehabilitation on Functional Recovery and Quality of Life in Thyroid Cancer Patients: A Comprehensive Review.

Cancers (Basel). 2023-9-10

[5]
Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.

Int J Mol Sci. 2023-7-6

[6]
PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages.

J Exp Clin Cancer Res. 2022-10-14

[7]
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer.

Nat Commun. 2022-7-8

[8]
Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis.

BMJ Open. 2022-6-22

[9]
Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.

Front Oncol. 2022-2-16

[10]
Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.

Breast Cancer Res. 2022-2-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索